China SXT Pharmaceuticals, Inc. (SXTC) 10-Year Financial Performance & Capital Metrics

SXTC • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareVitamins & Supplements

AboutChina SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The company offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of March 31, 2022, it had an end-customer base of 68 pharmaceutical companies, 14 chain pharmacies, and 20 hospitals in 10 provinces and municipalities in China. The company was founded in 2005 and is headquartered in Taizhou, China.Show more

Revenue $2M -9.7%
EBITDA -$3M -12.4%
Net Income -$3M -6.6%
EPS (Diluted) -8.18 -129.1%
Gross Margin 21.11% -26.5%
EBITDA Margin -149.24% -24.5%
Operating Margin -153.97% -18.1%
Net Margin -189.77% -18.1%
ROE -22.5% -3.9%
ROIC -141.97% -110.2%
Debt/Equity 0.06 -66.5%
Interest Coverage -4.14 +10.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 53.4% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 0 (bottom 0%)
✗Sales declining 19.5% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-19.54%

3Y-12.54%

TTM-27.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM58.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM76.69%

ROCE

10Y Avg16.12%

5Y Avg-24.02%

3Y Avg-23.58%

Latest-17.94%

Peer Comparison

Vitamins & Supplements

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SISIShineco, Inc.	187.33K	0.21	0	16.81%	-398.53%	-149.29%		0.81
SXTCChina SXT Pharmaceuticals, Inc.	13.57M	0.11	-0.01	-9.73%	-189.77%	-21.4%		0.06

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	3.72M	4.88M	7.02M	7.01M	5.16M	4.78M	2.6M	1.97M	1.93M	1.74M
Revenue Growth %	-	0.31%	0.44%	-0%	-0.26%	-0.07%	-0.46%	-0.24%	-0.02%	-0.1%
Cost of Goods Sold+	2.92M	2.57M	3.62M	2.4M	2.46M	1.94M	1.35M	1.55M	1.37M	1.37M
COGS % of Revenue	0.79%	0.53%	0.52%	0.34%	0.48%	0.41%	0.52%	0.78%	0.71%	0.79%
Gross Profit+	793.99K	2.31M	3.4M	4.61M	2.7M	2.84M	1.25M	426.27K	553.97K	367.43K
Gross Margin %	0.21%	0.47%	0.48%	0.66%	0.52%	0.59%	0.48%	0.22%	0.29%	0.21%
Gross Profit Growth %	-	1.91%	0.47%	0.36%	-0.41%	0.05%	-0.56%	-0.66%	0.3%	-0.34%
Operating Expenses+	584.85K	709.82K	1.77M	2.84M	4.04M	5.04M	6.44M	6.03M	3.07M	3.05M
OpEx % of Revenue	0.16%	0.15%	0.25%	0.41%	0.78%	1.05%	2.48%	3.06%	1.59%	1.75%
Selling, General & Admin	584.85K	709.82K	1.77M	2.84M	4.04M	5.04M	6.44M	6.03M	3.07M	3.05M
SG&A % of Revenue	0.16%	0.15%	0.25%	0.41%	0.78%	1.05%	2.48%	3.06%	1.59%	1.75%
Research & Development	0	0	0	0	0	0	0	0	184.19K	191.39K
R&D % of Revenue	-	-	-	-	-	-	-	-	0.1%	0.11%
Other Operating Expenses	0	0	-3.8K	27.14K	0	0	0	0	-184.19K	-191.39K
Operating Income+	209.14K	1.6M	1.63M	1.77M	4.28M	-2.2M	-5.19M	-5.61M	-2.52M	-2.68M
Operating Margin %	0.06%	0.33%	0.23%	0.25%	0.83%	-0.46%	-1.99%	-2.84%	-1.3%	-1.54%
Operating Income Growth %	-	6.66%	0.02%	0.08%	1.42%	-1.51%	-1.36%	-0.08%	0.55%	-0.07%
EBITDA+	298.1K	1.7M	1.76M	1.95M	4.62M	-1.85M	-4.87M	-5.36M	-2.31M	-2.6M
EBITDA Margin %	0.08%	0.35%	0.25%	0.28%	0.89%	-0.39%	-1.87%	-2.72%	-1.2%	-1.49%
EBITDA Growth %	-	4.71%	0.04%	0.11%	1.37%	-1.4%	-1.63%	-0.1%	0.57%	-0.12%
D&A (Non-Cash Add-back)	88.96K	99.23K	129.44K	180.92K	331.84K	345.41K	320.01K	250.16K	203.25K	82.3K
EBIT	209.14K	1.6M	1.63M	1.8M	-1.34M	-2.2M	-5.37M	-5.46M	-2.55M	-2.66M
Net Interest Income+	0	-40.39K	-779	-5.17K	-3.35M	-1.62M	-36.7K	-476.78K	-544.28K	-648.22K
Interest Income	51.06K	0	0	5.17K	0	0	0	0	0	0
Interest Expense	0	40.39K	779	5.17K	3.35M	1.62M	36.7K	476.78K	544.28K	648.22K
Other Income/Expense	-20.41K	-21.99K	-4.58K	21.97K	-9.05M	-743.79K	-218.28K	-327.26K	-583.32K	-623.17K
Pretax Income+	188.72K	1.58M	1.63M	1.79M	-10.39M	-2.94M	-5.41M	-5.93M	-3.1M	-3.3M
Pretax Margin %	0.05%	0.32%	0.23%	0.26%	-2.01%	-0.62%	-2.08%	-3.01%	-1.61%	-1.9%
Income Tax+	47.18K	395.05K	440.1K	252.23K	-101.72K	-192.68K	328.15K	0	0	0
Effective Tax Rate %	0.75%	0.75%	0.73%	0.86%	0.99%	0.93%	1.06%	1%	1%	1%
Net Income+	141.54K	1.19M	1.19M	1.54M	-10.29M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Net Margin %	0.04%	0.24%	0.17%	0.22%	-1.99%	-0.58%	-2.2%	-3.01%	-1.61%	-1.9%
Net Income Growth %	-	7.37%	0%	0.3%	-7.68%	0.73%	-1.09%	-0.03%	0.48%	-0.07%
Net Income (Continuing)	141.54K	1.19M	1.19M	1.54M	-10.29M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.00	0.00	0.00	149.67	-832.08	-95.48	-137.92	-22.23	-3.57	-8.18
EPS Growth %	-	-	-	-	-6.56%	0.89%	-0.44%	0.84%	0.84%	-1.29%
EPS (Basic)	0.00	0.00	0.00	149.67	-832.08	-95.48	-137.92	-22.23	-3.57	-8.18
Diluted Shares Outstanding	0	0	0	10.28K	12.36K	28.78K	41.59K	266.97K	867.42K	403.92K
Basic Shares Outstanding	0	0	0	10.28K	12.36K	28.78K	41.59K	266.97K	867.42K	403.92K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	5.83M	4.91M	6.1M	15.59M	19.64M	23.23M	22.45M	19.52M	14.23M	21.3M
Cash & Short-Term Investments	11.44K	65.57K	560.25K	9.13M	7.29M	13.33M	15.52M	17.37M	12.07M	18.1M
Cash Only	11.44K	65.57K	560.25K	9.13M	7.29M	13.33M	15.52M	17.37M	12.07M	18.1M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.06M	3.21M	3.91M	4.93M	10.65M	7.77M	5.53M	1.34M	1.35M	1.9M
Days Sales Outstanding	398.9	239.72	203.48	256.75	752.83	593.38	775.01	248.91	254.83	398.39
Inventory	1.72M	1.02M	1.27M	1.01M	892.77K	859.7K	1.02M	531.25K	809.76K	828.05K
Days Inventory Outstanding	214.47	144.66	127.82	153.26	132.54	161.91	274.98	125.47	215.03	220.05
Other Current Assets	31.7K	615.15K	134.73K	197.8K	654.96K	754.12K	384.55K	230.64K	6.84K	30.41K
Total Non-Current Assets+	471.48K	526.3K	1.56M	1.88M	2.07M	11.31M	11.09M	10.03M	8.89M	367.02K
Property, Plant & Equipment	430.08K	485.29K	1.49M	1.81M	1.9M	1.79M	1.59M	1.27M	564.69K	355.21K
Fixed Asset Turnover	8.65x	10.06x	4.71x	3.88x	2.71x	2.67x	1.64x	1.55x	3.42x	4.90x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	41.4K	41K	60.67K	61.1K	50.05K	45.8K	38.76K	27.87K	19.1K	11.81K
Long-Term Investments	0	0	-6.17K	-13.5K	-441.21K	0	0	0	0	0
Other Non-Current Assets	0	0	6.17K	13.5K	441.21K	9.16M	9.46M	8.74M	8.31M	0
Total Assets+	6.3M	5.43M	7.66M	17.47M	21.7M	34.55M	33.55M	29.55M	23.13M	21.66M
Asset Turnover	0.59x	0.90x	0.92x	0.40x	0.24x	0.14x	0.08x	0.07x	0.08x	0.08x
Asset Growth %	-	-0.14%	0.41%	1.28%	0.24%	0.59%	-0.03%	-0.12%	-0.22%	-0.06%
Total Current Liabilities+	5.55M	3.58M	4.37M	6.32M	12.26M	18.58M	17.12M	14.5M	8.9M	6.01M
Accounts Payable	2.89M	1.26M	2.41M	1.69M	1.94M	1.46M	1.48M	1.38M	1.28M	1.16M
Days Payables Outstanding	360.39	179.63	242.88	256.27	288.18	274.3	400.55	325.43	339.77	307.82
Short-Term Debt	479.23K	302.17K	385.12K	261.15K	6.69M	37.12K	2.05M	3.33M	2.29M	710.97K
Deferred Revenue (Current)	543.94K	0	292.95K	57.55K	298.04K	257.45K	77.37K	165.53K	187.66K	58.63K
Other Current Liabilities	1.54M	1.67M	1.27M	3.03M	1.96M	15.2M	122.77K	7.84M	3.06M	728.28K
Current Ratio	1.05x	1.37x	1.40x	2.47x	1.60x	1.25x	1.31x	1.35x	1.60x	3.54x
Quick Ratio	0.74x	1.09x	1.11x	2.31x	1.53x	1.20x	1.25x	1.31x	1.51x	3.40x
Cash Conversion Cycle	252.98	204.75	88.42	153.74	597.19	480.99	649.44	48.96	130.09	310.63
Total Non-Current Liabilities+	0	0	0	41.71K	36.51K	6.29K	0	365.82K	294.67K	211.68K
Long-Term Debt	0	0	0	41.71K	36.51K	6.29K	0	117.86K	117.13K	96.26K
Capital Lease Obligations	0	0	0	0	0	0	0	247.96K	177.54K	115.42K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	5.55M	3.58M	4.37M	6.36M	12.3M	18.59M	17.12M	14.86M	9.2M	6.22M
Total Debt+	479.23K	302.17K	385.12K	261.15K	6.72M	43.41K	2.05M	3.76M	2.65M	983.88K
Net Debt	467.79K	236.6K	-175.13K	-8.87M	-563.16K	-13.29M	-13.48M	-13.61M	-9.42M	-17.12M
Debt / Equity	0.65x	0.16x	0.12x	0.02x	0.72x	0.00x	0.12x	0.26x	0.19x	0.06x
Debt / EBITDA	1.61x	0.18x	0.22x	0.13x	1.46x	-	-	-	-	-
Net Debt / EBITDA	1.57x	0.14x	-0.10x	-4.55x	-0.12x	-	-	-	-	-
Interest Coverage	-	39.67x	2095.34x	342.00x	1.28x	-1.36x	-141.43x	-11.76x	-4.62x	-4.14x
Total Equity+	742.77K	1.85M	3.29M	11.11M	9.4M	15.96M	16.42M	14.69M	13.93M	15.44M
Equity Growth %	-	1.49%	0.77%	2.38%	-0.15%	0.7%	0.03%	-0.11%	-0.05%	0.11%
Book Value per Share	-	-	-	1080.10	760.38	554.56	394.91	55.03	16.06	38.22
Total Shareholders' Equity	742.77K	1.85M	3.29M	11.11M	9.4M	15.96M	16.42M	14.69M	13.93M	15.44M
Common Stock	20K	20K	20K	22.71K	34.67K	62.06K	162.47K	913.78K	4.35M	44.53M
Retained Earnings	-828.08K	357.06K	1.54M	3.08M	-7.2M	-9.95M	-15.69M	-21.61M	-24.71M	-28.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	87.09K	11.82K	257.37K	50.4K	-590.66K	527.79K	956.14K	-197.57K	-1.03M	-1.08M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	182.47K	293.04K	1.92M	239.19K	934.25K	-1.32M	268.29K	-80.76K	-1.93M	-2.35M
Operating CF Margin %	0.05%	0.06%	0.27%	0.03%	0.18%	-0.28%	0.1%	-0.04%	-1%	-1.35%
Operating CF Growth %	-	0.61%	5.55%	-0.88%	2.91%	-2.41%	1.2%	-1.3%	-22.87%	-0.22%
Net Income	141.54K	1.19M	1.19M	1.54M	-7.94M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Depreciation & Amortization	88.96K	99.23K	129.44K	180.92K	331.84K	345.41K	320.01K	250.16K	203.25K	82.3K
Stock-Based Compensation	0	0	0	0	0	0	2.33M	554.57K	352.1K	0
Deferred Taxes	0	0	-5.85K	-7.72K	-101.72K	-192.68K	328.15K	3.23M	0	0
Other Non-Cash Items	1.34M	1.44M	-2	66.89K	6.7M	2.89M	1.12M	408.69K	996.69K	1.85M
Working Capital Changes	-58.63K	-991.33K	608.99K	-1.54M	1.95M	-1.61M	1.9M	1.42M	-381.56K	-971.74K
Change in Receivables	-1.03M	-942.97K	384.43K	-1.81M	104K	-519.24K	831.47K	912.95K	-321.42K	-480.56K
Change in Inventory	-57.41K	384.22K	-274.38K	177.64K	39.71K	38.62K	-180.8K	408.95K	-190.29K	-14.53K
Change in Payables	-65.06K	-1.47M	966.57K	-567.31K	302.27K	-619.54K	-22.79K	9.7K	-29.25K	-114.08K
Cash from Investing+	-95.76K	-186.31K	-1.14M	-610.09K	-5.5M	-5.81M	-46.91K	-12.3K	26.42K	63.52K
Capital Expenditures	-96.99K	-186.31K	-1.05M	-610.09K	-406.66K	-93.04K	-62.49K	-70.68K	-7.06K	-2.02K
CapEx % of Revenue	0.03%	0.04%	0.15%	0.09%	0.08%	0.02%	0.02%	0.04%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-36.04K	-7.13K	-92.42K	-11.28K	-1.5M	3.13M	15.58K	58.38K	33.49K	65.54K
Cash from Financing+	-128.59K	-50.56K	-314.22K	9.04M	3.02M	12.41M	1.6M	2.94M	-2.62M	8.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-128.59K	-50.56K	0	2.48M	-5.78M	12.53M	-4.29M	-3.26M	-3.93M	5.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	85.48K	106.73K	869.44K	-370.89K	527.59K	-1.41M	205.8K	-151.44K	-1.94M	-2.35M
FCF Margin %	0.02%	0.02%	0.12%	-0.05%	0.1%	-0.3%	0.08%	-0.08%	-1%	-1.35%
FCF Growth %	-	0.25%	7.15%	-1.43%	2.42%	-3.67%	1.15%	-1.74%	-11.78%	-0.21%
FCF per Share	-	-	-	-36.07	42.67	-48.98	4.95	-0.57	-2.23	-5.81
FCF Conversion (FCF/Net Income)	1.29x	0.25x	1.62x	0.16x	-0.09x	0.48x	-0.05x	0.01x	0.62x	0.71x
Interest Paid	0	197	0	1.49K	287.81K	5.55K	3.2K	0	0	21.24K
Taxes Paid	0	7.09K	22.36K	51.76K	10.36K	3.08K	16.73K	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	19.06%	91.33%	46.22%	21.39%	-100.32%	-21.67%	-35.42%	-38.15%	-21.65%	-22.5%
Return on Invested Capital (ROIC)	12.96%	72.83%	47.09%	49.62%	58.03%	-28.63%	-138.55%	-208.91%	-67.53%	-141.97%
Gross Margin	21.35%	47.36%	48.46%	65.77%	52.37%	59.44%	48.1%	21.62%	28.73%	21.11%
Net Margin	3.81%	24.28%	16.92%	21.95%	-199.29%	-57.52%	-220.43%	-301%	-160.67%	-189.77%
Debt / Equity	0.65x	0.16x	0.12x	0.02x	0.72x	0.00x	0.12x	0.26x	0.19x	0.06x
Interest Coverage	-	39.67x	2095.34x	342.00x	1.28x	-1.36x	-141.43x	-11.76x	-4.62x	-4.14x
FCF Conversion	1.29x	0.25x	1.62x	0.16x	-0.09x	0.48x	-0.05x	0.01x	0.62x	0.71x
Revenue Growth	-	31.27%	43.79%	-0.1%	-26.38%	-7.45%	-45.53%	-24.23%	-2.19%	-9.73%

Frequently Asked Questions

Growth & Financials

China SXT Pharmaceuticals, Inc. (SXTC) reported $1.7M in revenue for fiscal year 2025. This represents a 53% decrease from $3.7M in 2016.

China SXT Pharmaceuticals, Inc. (SXTC) saw revenue decline by 9.7% over the past year.

China SXT Pharmaceuticals, Inc. (SXTC) reported a net loss of $3.3M for fiscal year 2025.

Dividend & Returns

China SXT Pharmaceuticals, Inc. (SXTC) has a return on equity (ROE) of -22.5%. Negative ROE indicates the company is unprofitable.

China SXT Pharmaceuticals, Inc. (SXTC) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.

US Stock Screener

...

China SXT Pharmaceuticals, Inc. (SXTC) 10-Year Financial Performance & Capital Metrics

SXTC • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareVitamins & Supplements

Revenue $2M -9.7%
EBITDA -$3M -12.4%
Net Income -$3M -6.6%
EPS (Diluted) -8.18 -129.1%
Gross Margin 21.11% -26.5%
EBITDA Margin -149.24% -24.5%
Operating Margin -153.97% -18.1%
Net Margin -189.77% -18.1%
ROE -22.5% -3.9%
ROIC -141.97% -110.2%
Debt/Equity 0.06 -66.5%
Interest Coverage -4.14 +10.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Share count reduced 53.4% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 0 (bottom 0%)
✗Sales declining 19.5% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-19.54%

3Y-12.54%

TTM-27.41%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM58.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM76.69%

ROCE

10Y Avg16.12%

5Y Avg-24.02%

3Y Avg-23.58%

Latest-17.94%

Peer Comparison

Vitamins & Supplements

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SISIShineco, Inc.	187.33K	0.21	0	16.81%	-398.53%	-149.29%		0.81
SXTCChina SXT Pharmaceuticals, Inc.	13.57M	0.11	-0.01	-9.73%	-189.77%	-21.4%		0.06

Profit & Loss

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	3.72M	4.88M	7.02M	7.01M	5.16M	4.78M	2.6M	1.97M	1.93M	1.74M
Revenue Growth %	-	0.31%	0.44%	-0%	-0.26%	-0.07%	-0.46%	-0.24%	-0.02%	-0.1%
Cost of Goods Sold+	2.92M	2.57M	3.62M	2.4M	2.46M	1.94M	1.35M	1.55M	1.37M	1.37M
COGS % of Revenue	0.79%	0.53%	0.52%	0.34%	0.48%	0.41%	0.52%	0.78%	0.71%	0.79%
Gross Profit+	793.99K	2.31M	3.4M	4.61M	2.7M	2.84M	1.25M	426.27K	553.97K	367.43K
Gross Margin %	0.21%	0.47%	0.48%	0.66%	0.52%	0.59%	0.48%	0.22%	0.29%	0.21%
Gross Profit Growth %	-	1.91%	0.47%	0.36%	-0.41%	0.05%	-0.56%	-0.66%	0.3%	-0.34%
Operating Expenses+	584.85K	709.82K	1.77M	2.84M	4.04M	5.04M	6.44M	6.03M	3.07M	3.05M
OpEx % of Revenue	0.16%	0.15%	0.25%	0.41%	0.78%	1.05%	2.48%	3.06%	1.59%	1.75%
Selling, General & Admin	584.85K	709.82K	1.77M	2.84M	4.04M	5.04M	6.44M	6.03M	3.07M	3.05M
SG&A % of Revenue	0.16%	0.15%	0.25%	0.41%	0.78%	1.05%	2.48%	3.06%	1.59%	1.75%
Research & Development	0	0	0	0	0	0	0	0	184.19K	191.39K
R&D % of Revenue	-	-	-	-	-	-	-	-	0.1%	0.11%
Other Operating Expenses	0	0	-3.8K	27.14K	0	0	0	0	-184.19K	-191.39K
Operating Income+	209.14K	1.6M	1.63M	1.77M	4.28M	-2.2M	-5.19M	-5.61M	-2.52M	-2.68M
Operating Margin %	0.06%	0.33%	0.23%	0.25%	0.83%	-0.46%	-1.99%	-2.84%	-1.3%	-1.54%
Operating Income Growth %	-	6.66%	0.02%	0.08%	1.42%	-1.51%	-1.36%	-0.08%	0.55%	-0.07%
EBITDA+	298.1K	1.7M	1.76M	1.95M	4.62M	-1.85M	-4.87M	-5.36M	-2.31M	-2.6M
EBITDA Margin %	0.08%	0.35%	0.25%	0.28%	0.89%	-0.39%	-1.87%	-2.72%	-1.2%	-1.49%
EBITDA Growth %	-	4.71%	0.04%	0.11%	1.37%	-1.4%	-1.63%	-0.1%	0.57%	-0.12%
D&A (Non-Cash Add-back)	88.96K	99.23K	129.44K	180.92K	331.84K	345.41K	320.01K	250.16K	203.25K	82.3K
EBIT	209.14K	1.6M	1.63M	1.8M	-1.34M	-2.2M	-5.37M	-5.46M	-2.55M	-2.66M
Net Interest Income+	0	-40.39K	-779	-5.17K	-3.35M	-1.62M	-36.7K	-476.78K	-544.28K	-648.22K
Interest Income	51.06K	0	0	5.17K	0	0	0	0	0	0
Interest Expense	0	40.39K	779	5.17K	3.35M	1.62M	36.7K	476.78K	544.28K	648.22K
Other Income/Expense	-20.41K	-21.99K	-4.58K	21.97K	-9.05M	-743.79K	-218.28K	-327.26K	-583.32K	-623.17K
Pretax Income+	188.72K	1.58M	1.63M	1.79M	-10.39M	-2.94M	-5.41M	-5.93M	-3.1M	-3.3M
Pretax Margin %	0.05%	0.32%	0.23%	0.26%	-2.01%	-0.62%	-2.08%	-3.01%	-1.61%	-1.9%
Income Tax+	47.18K	395.05K	440.1K	252.23K	-101.72K	-192.68K	328.15K	0	0	0
Effective Tax Rate %	0.75%	0.75%	0.73%	0.86%	0.99%	0.93%	1.06%	1%	1%	1%
Net Income+	141.54K	1.19M	1.19M	1.54M	-10.29M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Net Margin %	0.04%	0.24%	0.17%	0.22%	-1.99%	-0.58%	-2.2%	-3.01%	-1.61%	-1.9%
Net Income Growth %	-	7.37%	0%	0.3%	-7.68%	0.73%	-1.09%	-0.03%	0.48%	-0.07%
Net Income (Continuing)	141.54K	1.19M	1.19M	1.54M	-10.29M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.00	0.00	0.00	149.67	-832.08	-95.48	-137.92	-22.23	-3.57	-8.18
EPS Growth %	-	-	-	-	-6.56%	0.89%	-0.44%	0.84%	0.84%	-1.29%
EPS (Basic)	0.00	0.00	0.00	149.67	-832.08	-95.48	-137.92	-22.23	-3.57	-8.18
Diluted Shares Outstanding	0	0	0	10.28K	12.36K	28.78K	41.59K	266.97K	867.42K	403.92K
Basic Shares Outstanding	0	0	0	10.28K	12.36K	28.78K	41.59K	266.97K	867.42K	403.92K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	5.83M	4.91M	6.1M	15.59M	19.64M	23.23M	22.45M	19.52M	14.23M	21.3M
Cash & Short-Term Investments	11.44K	65.57K	560.25K	9.13M	7.29M	13.33M	15.52M	17.37M	12.07M	18.1M
Cash Only	11.44K	65.57K	560.25K	9.13M	7.29M	13.33M	15.52M	17.37M	12.07M	18.1M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	4.06M	3.21M	3.91M	4.93M	10.65M	7.77M	5.53M	1.34M	1.35M	1.9M
Days Sales Outstanding	398.9	239.72	203.48	256.75	752.83	593.38	775.01	248.91	254.83	398.39
Inventory	1.72M	1.02M	1.27M	1.01M	892.77K	859.7K	1.02M	531.25K	809.76K	828.05K
Days Inventory Outstanding	214.47	144.66	127.82	153.26	132.54	161.91	274.98	125.47	215.03	220.05
Other Current Assets	31.7K	615.15K	134.73K	197.8K	654.96K	754.12K	384.55K	230.64K	6.84K	30.41K
Total Non-Current Assets+	471.48K	526.3K	1.56M	1.88M	2.07M	11.31M	11.09M	10.03M	8.89M	367.02K
Property, Plant & Equipment	430.08K	485.29K	1.49M	1.81M	1.9M	1.79M	1.59M	1.27M	564.69K	355.21K
Fixed Asset Turnover	8.65x	10.06x	4.71x	3.88x	2.71x	2.67x	1.64x	1.55x	3.42x	4.90x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	41.4K	41K	60.67K	61.1K	50.05K	45.8K	38.76K	27.87K	19.1K	11.81K
Long-Term Investments	0	0	-6.17K	-13.5K	-441.21K	0	0	0	0	0
Other Non-Current Assets	0	0	6.17K	13.5K	441.21K	9.16M	9.46M	8.74M	8.31M	0
Total Assets+	6.3M	5.43M	7.66M	17.47M	21.7M	34.55M	33.55M	29.55M	23.13M	21.66M
Asset Turnover	0.59x	0.90x	0.92x	0.40x	0.24x	0.14x	0.08x	0.07x	0.08x	0.08x
Asset Growth %	-	-0.14%	0.41%	1.28%	0.24%	0.59%	-0.03%	-0.12%	-0.22%	-0.06%
Total Current Liabilities+	5.55M	3.58M	4.37M	6.32M	12.26M	18.58M	17.12M	14.5M	8.9M	6.01M
Accounts Payable	2.89M	1.26M	2.41M	1.69M	1.94M	1.46M	1.48M	1.38M	1.28M	1.16M
Days Payables Outstanding	360.39	179.63	242.88	256.27	288.18	274.3	400.55	325.43	339.77	307.82
Short-Term Debt	479.23K	302.17K	385.12K	261.15K	6.69M	37.12K	2.05M	3.33M	2.29M	710.97K
Deferred Revenue (Current)	543.94K	0	292.95K	57.55K	298.04K	257.45K	77.37K	165.53K	187.66K	58.63K
Other Current Liabilities	1.54M	1.67M	1.27M	3.03M	1.96M	15.2M	122.77K	7.84M	3.06M	728.28K
Current Ratio	1.05x	1.37x	1.40x	2.47x	1.60x	1.25x	1.31x	1.35x	1.60x	3.54x
Quick Ratio	0.74x	1.09x	1.11x	2.31x	1.53x	1.20x	1.25x	1.31x	1.51x	3.40x
Cash Conversion Cycle	252.98	204.75	88.42	153.74	597.19	480.99	649.44	48.96	130.09	310.63
Total Non-Current Liabilities+	0	0	0	41.71K	36.51K	6.29K	0	365.82K	294.67K	211.68K
Long-Term Debt	0	0	0	41.71K	36.51K	6.29K	0	117.86K	117.13K	96.26K
Capital Lease Obligations	0	0	0	0	0	0	0	247.96K	177.54K	115.42K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	5.55M	3.58M	4.37M	6.36M	12.3M	18.59M	17.12M	14.86M	9.2M	6.22M
Total Debt+	479.23K	302.17K	385.12K	261.15K	6.72M	43.41K	2.05M	3.76M	2.65M	983.88K
Net Debt	467.79K	236.6K	-175.13K	-8.87M	-563.16K	-13.29M	-13.48M	-13.61M	-9.42M	-17.12M
Debt / Equity	0.65x	0.16x	0.12x	0.02x	0.72x	0.00x	0.12x	0.26x	0.19x	0.06x
Debt / EBITDA	1.61x	0.18x	0.22x	0.13x	1.46x	-	-	-	-	-
Net Debt / EBITDA	1.57x	0.14x	-0.10x	-4.55x	-0.12x	-	-	-	-	-
Interest Coverage	-	39.67x	2095.34x	342.00x	1.28x	-1.36x	-141.43x	-11.76x	-4.62x	-4.14x
Total Equity+	742.77K	1.85M	3.29M	11.11M	9.4M	15.96M	16.42M	14.69M	13.93M	15.44M
Equity Growth %	-	1.49%	0.77%	2.38%	-0.15%	0.7%	0.03%	-0.11%	-0.05%	0.11%
Book Value per Share	-	-	-	1080.10	760.38	554.56	394.91	55.03	16.06	38.22
Total Shareholders' Equity	742.77K	1.85M	3.29M	11.11M	9.4M	15.96M	16.42M	14.69M	13.93M	15.44M
Common Stock	20K	20K	20K	22.71K	34.67K	62.06K	162.47K	913.78K	4.35M	44.53M
Retained Earnings	-828.08K	357.06K	1.54M	3.08M	-7.2M	-9.95M	-15.69M	-21.61M	-24.71M	-28.02M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	87.09K	11.82K	257.37K	50.4K	-590.66K	527.79K	956.14K	-197.57K	-1.03M	-1.08M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	182.47K	293.04K	1.92M	239.19K	934.25K	-1.32M	268.29K	-80.76K	-1.93M	-2.35M
Operating CF Margin %	0.05%	0.06%	0.27%	0.03%	0.18%	-0.28%	0.1%	-0.04%	-1%	-1.35%
Operating CF Growth %	-	0.61%	5.55%	-0.88%	2.91%	-2.41%	1.2%	-1.3%	-22.87%	-0.22%
Net Income	141.54K	1.19M	1.19M	1.54M	-7.94M	-2.75M	-5.74M	-5.93M	-3.1M	-3.3M
Depreciation & Amortization	88.96K	99.23K	129.44K	180.92K	331.84K	345.41K	320.01K	250.16K	203.25K	82.3K
Stock-Based Compensation	0	0	0	0	0	0	2.33M	554.57K	352.1K	0
Deferred Taxes	0	0	-5.85K	-7.72K	-101.72K	-192.68K	328.15K	3.23M	0	0
Other Non-Cash Items	1.34M	1.44M	-2	66.89K	6.7M	2.89M	1.12M	408.69K	996.69K	1.85M
Working Capital Changes	-58.63K	-991.33K	608.99K	-1.54M	1.95M	-1.61M	1.9M	1.42M	-381.56K	-971.74K
Change in Receivables	-1.03M	-942.97K	384.43K	-1.81M	104K	-519.24K	831.47K	912.95K	-321.42K	-480.56K
Change in Inventory	-57.41K	384.22K	-274.38K	177.64K	39.71K	38.62K	-180.8K	408.95K	-190.29K	-14.53K
Change in Payables	-65.06K	-1.47M	966.57K	-567.31K	302.27K	-619.54K	-22.79K	9.7K	-29.25K	-114.08K
Cash from Investing+	-95.76K	-186.31K	-1.14M	-610.09K	-5.5M	-5.81M	-46.91K	-12.3K	26.42K	63.52K
Capital Expenditures	-96.99K	-186.31K	-1.05M	-610.09K	-406.66K	-93.04K	-62.49K	-70.68K	-7.06K	-2.02K
CapEx % of Revenue	0.03%	0.04%	0.15%	0.09%	0.08%	0.02%	0.02%	0.04%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-36.04K	-7.13K	-92.42K	-11.28K	-1.5M	3.13M	15.58K	58.38K	33.49K	65.54K
Cash from Financing+	-128.59K	-50.56K	-314.22K	9.04M	3.02M	12.41M	1.6M	2.94M	-2.62M	8.4M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-128.59K	-50.56K	0	2.48M	-5.78M	12.53M	-4.29M	-3.26M	-3.93M	5.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	85.48K	106.73K	869.44K	-370.89K	527.59K	-1.41M	205.8K	-151.44K	-1.94M	-2.35M
FCF Margin %	0.02%	0.02%	0.12%	-0.05%	0.1%	-0.3%	0.08%	-0.08%	-1%	-1.35%
FCF Growth %	-	0.25%	7.15%	-1.43%	2.42%	-3.67%	1.15%	-1.74%	-11.78%	-0.21%
FCF per Share	-	-	-	-36.07	42.67	-48.98	4.95	-0.57	-2.23	-5.81
FCF Conversion (FCF/Net Income)	1.29x	0.25x	1.62x	0.16x	-0.09x	0.48x	-0.05x	0.01x	0.62x	0.71x
Interest Paid	0	197	0	1.49K	287.81K	5.55K	3.2K	0	0	21.24K
Taxes Paid	0	7.09K	22.36K	51.76K	10.36K	3.08K	16.73K	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	19.06%	91.33%	46.22%	21.39%	-100.32%	-21.67%	-35.42%	-38.15%	-21.65%	-22.5%
Return on Invested Capital (ROIC)	12.96%	72.83%	47.09%	49.62%	58.03%	-28.63%	-138.55%	-208.91%	-67.53%	-141.97%
Gross Margin	21.35%	47.36%	48.46%	65.77%	52.37%	59.44%	48.1%	21.62%	28.73%	21.11%
Net Margin	3.81%	24.28%	16.92%	21.95%	-199.29%	-57.52%	-220.43%	-301%	-160.67%	-189.77%
Debt / Equity	0.65x	0.16x	0.12x	0.02x	0.72x	0.00x	0.12x	0.26x	0.19x	0.06x
Interest Coverage	-	39.67x	2095.34x	342.00x	1.28x	-1.36x	-141.43x	-11.76x	-4.62x	-4.14x
FCF Conversion	1.29x	0.25x	1.62x	0.16x	-0.09x	0.48x	-0.05x	0.01x	0.62x	0.71x
Revenue Growth	-	31.27%	43.79%	-0.1%	-26.38%	-7.45%	-45.53%	-24.23%	-2.19%	-9.73%

Frequently Asked Questions

Growth & Financials

China SXT Pharmaceuticals, Inc. (SXTC) reported $1.7M in revenue for fiscal year 2025. This represents a 53% decrease from $3.7M in 2016.

China SXT Pharmaceuticals, Inc. (SXTC) saw revenue decline by 9.7% over the past year.

China SXT Pharmaceuticals, Inc. (SXTC) reported a net loss of $3.3M for fiscal year 2025.

Dividend & Returns

China SXT Pharmaceuticals, Inc. (SXTC) has a return on equity (ROE) of -22.5%. Negative ROE indicates the company is unprofitable.

China SXT Pharmaceuticals, Inc. (SXTC) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.